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Aim of the study: Melatonin (MLT) is 
reported to exert uroprotective effect 
due to its antioxidant/anti-inflamma-
tory properties. It is unknown whether 
that effect also results from melatonin 
receptor activation, or it is attributed 
to the modulation of the autonomic 
nervous system (ANS) activity.
Our purpose was to evaluate the effect 
of MLT and agomelatine (AMT) – mela-
tonin receptor agonist on ANS activity, 
indirectly assessed by heart rate vari-
ability (HRV), in rats with cyclophos-
phamide-induced hemorrhagic cystitis 
(CP-HC).
Material and methods: CP-HC was in-
duced in all rats by four doses of cyclo-
phosphamide given intraperitoneally 
(i.p.) at the dose of 75 mg/kg/dose. 
Rats were divided on three experi-
mental groups and during induction 
of cystitis were treated i.p. with: (1) sa-
line (control group); (2A/2B) MTL given 
at the dose of 40 or 100 mg/kg/dose; 
(3A/3B) AMT given at the dose of 40 or 
100 mg/kg/dose. HRV recordings were 
performed in anesthetized rats at the 
eight day of the study.
Results: Both 2A and 2B animals were 
characterized by an increase in all 
non-normalized components in HRV 
spectrum. Furthermore, normalized LF 
(nLF) increase along with normalized 
HF (nHF) decrease were demonstrat-
ed in 2B rats. AMT treatment result-
ed only in an increase in total power 
(TP) and very low frequency (VLF) in 
3A animals.
Conclusions: CP-HC rats treated with 
MLT were characterized by global ANS 
activity elevation, with a marked sym-
pathetic tone predominance in sub-
group 2B. Since the AMT treatment 
had no effect on autonomic function, 
it seems that melatonin modulates 
autonomic activity via non-receptor 
mechanisms. 
Key words: cyclophosphamide, hemor-
rhagic cystitis, autonomic nervous sys-
tem, heart rate variability, melatonin, 
agomelatine.
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Introduction
Hemorrhagic cystitis (HC), defined as diffuse inflammation of the bladder 
characterized by hemorrhagic mucosal lesions, is manifested by haematuria 
and the symptoms of lower urinary tract (LUTS), i.e. dysuria, increased void-
ing frequency, urinary urgency, nocturia and suprapubic pain [1, 2]. An acute 
HC can be caused by both infectious and non-infectious agents, but also its 
iatrogenic form is recognized in clinical practice as a consequence of chemo-
therapy with oxazaphosphorine agents, cyclophosphamide (CP) or ifospha-
mide (IF) [1, 3]. The administration of cyclophosphamide is also associated 
with the additional risk of myocardial damage, resulting in the development 
of cardiomyopathy [4]. The pathogenesis of cyclophosphamide- or other 
oxazaphosphorine-induced HC is complex; the process is induced by toxic 
intrabladder metabolite of oxazaphosphorines, acrolein, and finally condi-
tioned by the release of multiple inflammatory mediators, exerting pleio-
tropic effect on bladder tissues. A more detailed description of CP-HC can be 
found in one of our previously published papers [5].
The standard prophylactic measures implemented during oxazaphospho-
rine treatment include intravenous or oral administration of sodium 2-mer-
captoethane sulfonate (mesna), which remains the most important uropro-
tector. That compound inactivates the toxic metabolite, acrolein, released 
during CP/IF intrabladder biotransformation, to non-toxic thiol derivatives 
[6]. Moreover, hemostatic preparations are administrated and bladder lav-
age with saline solution is performed to evacuate clots and maintain diu-
resis [2, 3].
Hemorrhagic cystitis still remains a clinical problem, especially in pa-
tients treated with high doses of CP, and the standard procedure mentioned 
above does not fully prevent from its development. Hence, new prophy-
lactic compounds are tested for their application in the CP-HC prevention. 
The results of previously published studies point to potential efficacy of in-
travesically administered diluted potassium aluminium sulphate (an astrin-
gent solution), silver nitrate, formalin or phenol (exerting cautering effect), 
oestrogens (modulating angiogenic processes) or vasopressin (exerting 
vasoconstriction effect) [7]. Nowadays, melatonin (MLT) is also among the 
tested agents. MLT is a potent free radical scavenger, antioxidant enzyme 
activator, a compound inhibiting lipid peroxidation and stabilizer of plasma 
membranes, which makes them less susceptible to inflammatory damage. 
Research has also demonstrated anti-inflammatory properties of MLT 
resulting from down-regulation of pro-inflammatory cytokines and nitric 
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oxide inhibition [8]. Melatonin could also alleviate urinary 
frequency by suppressing the brain micturition centre [9].
However, the pharmacodynamic description of MLT is 
still incomplete, and it is possible that melatonin is also 
an agent targeting the autonomic nervous system (ANS), 
as an additional pharmacological action. Hence, we aimed 
to determine whether melatonin modulates the ANS func-
tion in an experimental CP-HC model, and whether poten-
tial changes in autonomic regulation may contribute to its 
potential uroprotective properties. Moreover, our goal was 
also to assess the ANS response to agomelatine (AMT), 
an agonist of MT1/MT2 melatonin receptors with addition-
al antagonistic impact in relation to the receptors 5HT2c, 
but without additional melatonin-like antioxidant/anti- 
inflammatory properties [10, 11]. Using AMT, we tried to 
clarify either whether the potential neuromodulating ef-
fect of MLT may result from MT receptor activation, or if 
it is attributed to its additional non-receptor pharmacody-
namic mechanisms.
Material and methods
The medical experiment, which has been described 
in this paper, was approved by the First Local Ethi-
cal Committee for Animal Experiments in Krakow. 
The experiment was carried out using thirty 11-week-old 
albino Wistar rats, divided into three groups, ten individ-
uals each. Within 7 days, an experimental cyclophospha-
mide-induced hemorrhagic cystitis (CP-HC) was evoked 
in all studied animals, as described previously both 
Dinis et al. [12] and Chopra et al. [13]. CP-HC developed 
after four-time (in the first, third, fifth and seventh day 
of the experiment) intraperitoneal (i.p.) administration of 
cyclophosphamide, at a dose of 75 mg/kg b.w. The de-
velopment of CP-HC was confirmed by histopathological 
assessment of rats’ bladders, obtained at the end of 
the experiment. Furthermore, we used the same meth-
odology in our previous study, in which the presence of 
CP-HC-associated bladder overactivity was verified by 
urodynamic recordings [14].
Group 1 consisted of CP-HC control animals. The animals 
from other two groups, received i.p. melatonin (group 2) 
or agomelatine (group 3) 30 minutes after the CP admin-
istration. As two animals from the control group died be-
fore receiving the last, fourth CP dose, and one rat from 
group 3 did not complete the whole treatment, eventually 
these groups consisted of 8 and 9 animals, respectively. 
All animals from group 2 survived till the end of the study. 
All studied rats exhibited normal life activity, but their con-
dition and body weight progressively deteriorated due to 
the adverse, systemic effects of CP.
Due to the use of two doses of both MLT and AMT, 
groups 2 and 3 were divided into subgroups containing 
five individuals each: 2A or 2B, and 3A or 3B (40 mg/kg or 
100 mg/kg b.w. MLT or AMT, respectively). Control animals 
were given i.p. injections of saline instead of MLT/AMT 
treatment. The choice of MLT/AMT doses was consistent 
with the other published research (there are reports of MLT 
and AMT administered at 10–80 mg/kg b.w. and 10–50 mg/ 
kg b.w., respectively) [15–17]. Hence, we adopted 40 mg/ 
kg b.w. MLT/AMT as an “average” dose and 100 mg/kg b.w. 
as a “high” one. Moreover, we also used the same MLT/
AMT high dose in our previous study aimed at assessing 
the MLT/AMT influence on bladder motility in an exper-
imental model of CP-HC [14]. Melatonin was obtained in 
crystalline form from Sigma Aldrich, and agomelatine from 
the commercial preparation Valdoxan®, Servier (tablets 
containing 25 mg AMT). Both MLT and AMT, after prepa-
ration of the corresponding doses, were dissolved in water 
for injection, immediately prior to administration. On the 
eighth day of the experiment all of the studied animals 
were subjected to ECG recording, with subsequent anal-
ysis of heart rate variability (HRV). The ECG was recorded 
under general anaesthesia after urethane administration 
(1200 mg/kg, i.p.) and 20-min rest. Before recordings, the 
abdominal fur was removed, and the abrasive paste and 
standard ECG gel were applied. Recordings were collect-
ed with the paediatric Ag/AgCl use (EG-S30 PSG Sorimex), 
deployed in the classic configuration in order to obtain 
one ECG lead and ADInstruments hardware (Power Lab 
4/30 and BIO Amplifier). During registration, the animals 
remained under a heating lamp to prevent the decline 
in body temperature. Immediately prior to registration, 
the animals from subgroups 2A/2B and 3A/3B received 
the last, fifth MLT/AMT dose, whereas the control rats 
were given the last injection of saline.
Once registrations were completed, the ECG signal 
was visually evaluated to remove ectopic beats and the 
remaining records were subjected to HRV analysis in both 
time and frequency (spectral) domain, using ADInstru-
ments  software (Chart v5.4.2) for Mac OS X Version 10.1.2. 
The basis for the HRV analysis is the variability of the ad-
jacent, “normal-normal” (N-N) intervals duration, which 
is subject to continuous, ANS-modulated fluctuations. 
The other time-domain HRV parameters are secondary 
measures, based on mean N-N statistical parameters [18]. 
We analysed standard time-domain HRV parameters: the 
average duration of N-N intervals (mean N-N), the lon-
gest N-N interval (max N-N), the shortest N-N interval 
(min N-N), the global standard deviation of N-N intervals 
(SDN-N), the root mean square of the successive differenc-
es (rMSSD) – the successive differences being neighbour-
ing RR intervals (all in [ms]).
During the spectral HRV analysis, total power (TP) of 
HRV spectrum is determined along with the powers (in 
[ms2]) of its basic components, i.e. the distribution of N-N 
intervals with respect to the cyclic ANS-modulated activi-
ty of the sinus node, associated with three main essential 
rhythms: in the range of very low (VLF), low (LF) and high 
(HF) frequencies [18]. In this analysis, we adopted the fol-
lowing ranges for the individual spectral components of 
HRV: 0.18 < VLF < 0.28 < LF <0.78 < HF < 3. These frequen-
cy ranges were similar to those used by Aubert et al. [19] 
(0.19 < LF < 0.74 < HF < 2.5), and Goncalves et al. [20] 
(0.10 < LF < 1.0 < HF < 3.0). Subjecting the the HRV spec-
trum to the process of normalization, we also calculated 
the normalized nHF and nLF values, which are regarded 
to reflect the selective parasympathetic and sympathetic 
tension, respectively. The HRV spectrum normalization is 
based on the calculation of the sharing of relevant com-
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ponents (LF or HF) in total HRV power, excluding VLF com-
ponent power. This procedure results from the difficulties 
of interpretation regarding the VLF component [18, 21, 22] 
(see below in Discussion section).
Finally, after the administration of the lethal dose of so-
dium pentobarbital (400 mg/kg b.w.), a cystectomy was 
performed to measure the bladder wet weight (BWW) 
and to obtain specimens for histopathological evaluation. 
A bladder was collected from each of the study animals, 
following a previous separation from the surrounding adi-
pose tissue and voiding. According to literature, BWW 
may be considered an indirect measure of inflammatory 
remodelling of the bladder [23, 24]. Immediately after col-
lection, bladders were weighed on an analytic scale and 
then placed in 4% formalin solution with PBS for further 
histopathological evaluation. The finally prepared micro-
scopic sections were stained with hematoxylin and eosin 
(HE) to enable the histologic evaluation of the inflamma-
tion severity.
The HRV results were expressed as mean ±SD. Statistical 
analysis was performed using analysis of variance (ANOVA), 
which verifies the existence of statistically significant differ-
ences between three studied populations. Whenever statis-
tically significant differences were demonstrated (p < 0.05 
on ANOVA test), the significance of differences between 
paired (1-2A, 1-2B, 1-3A and 1-3B) populations was tested 
using the Student’s t-test. All statistical calculations were 
performed on values subjected to logarithmic transforma-
tion in order to ensure greater consistency of analysed HRV 
parameters with normal distribution.
Results
Characteristics of the studied groups
In all analysed groups, a progressive decrease in body 
weight, associated with the subsequent doses of the CP, 
was noted. On the 7th day of the experiment, the ani-
mals from subgroup 2B were characterized by the lowest 
body weight, while the control group by the highest one. 
A similar dependence was found in the case of mean body 
weight for all studied groups. However, these differences 
were not statistically significant. Detailed data are provid-
ed in Table 1.
Assessment of the collected bladders
Bladder wet weight measurement showed that the ani-
mals treated with MLT (subgroup 2A and 2B) were char-
acterized by slightly higher BWW values compared to 
animals treated with AMT (subgroups 3A and 3B) and to 
the controls. These differences were not statistically sig-
nificant. The detailed results are also given in Table 1. 
The histopathological examination of bladder specimens 
confirmed the presence of inflammatory lesions in all 
studied groups.
Bladders collected from control rats were character-
ized by a clear oedema and signs of congestion (mostly in 
the mucosa), along with signs of focal proliferation of fi-
broblasts in the mucosal lamina propria, mostly around 
some fine submucosal blood extravasations. Fine lympho-
cytic inflammatory infiltrations were visible in the vicinity 
of vessels of the mucosal lamina propria. Epithelium of 
the bladder lining demonstrated focal ulceration with signs 
of clear proliferation of cells. Complex papillary architec-
ture showing anastomosis of papillae with focally irregular 
nuclei and few scattered mitotic figures was intensified in 
subgroups 3A/3B, while signs of oedema and hyperaemia 
were revealed in subgroups 2A/2B (MLT treatment) and in 
the controls; the lesions documented in subgroups 2A/2B 
was slightly lower than in the controls.
Results of HRV analysis
Time-domain HRV analysis
The animals treated with MLT, regardless of the MLT 
dose, were characterized by the highest values of mean 
and maximum N-N interval, with concurrently the lowest 
value of min N-N from all groups. The differences related 
to mean N-N were statistically significant. Additionally, 
rats from subgroups 2A and 2B were characterized by the 
lowest average heart rate, and the highest SDN-N and 
rMSSD values. These differences turned out to be statis-
tically significant when compared to the controls. Most of 
the time-domain HRV parameters recorded in AMT-treat-
ed animals did not differ significantly from respective val-
ues of the controls, except for the average HR and rMSSD 
(these parameters were significantly lower) and mean N-N 
(it was higher) in animals from subgroup 3A and average 
Table 1. The body weight [g] and bladder wet weight (BWW) [mg] of the studied animals (mean ±SD)
Body weight BWW
1st day – 1st dose 3rd day – 2nd dose 5th day – 3rd dose 7th day – 4th dose Mean body weight
Group 1
Control
288.0 ±11.8 284.5 ±9.1 283.7 ±9.4 281.7 ±10.6 284.5 ±3.6 181.9 ±4.6 
Subgroup 2A
CP-HC + MLT 40
286.7 ±16.6 284.7 ±28.0 273.7 ±26.9 258.7 ±23.6 275.9 ±12.8 191. 7 ±5.4
Subgroup 2B
CP-HC + MLT 100
274.7 ±16.2 268.0 ±10.4 260.0 ±8.7 246.0 ±9.9 262.2 ±12.3 209.6 ±6.1
Subgroup 3A
CP-HC + AMT 40
281.3 ±8.1 278.0 ±6.9 272.0 ±8.7 256.3 ±3.8 271.9 ±11.1 184.6 ±4.4
Subgroup 3B
CP-HC + AMT 100
279.7 ±13.3 279.3 ±16.7 276.7 ±16.3 267.3 ±13.6 275.8 ±5.7 192.1 ±4.3
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HR (lower value) in rats from subgroup 3B. Detailed results 
of the time-domain HRV parameters, including statistical 
conclusions, are presented in Table 2.
 
Spectral (frequency) HRV analysis
The spectral analysis carried out in MLT-treated animals 
revealed statistically significant differences for the total 
power value of the HRV spectrum, and for all non-normal-
ized parameters: VLF, LF and HF. They achieved significantly 
higher values in animals treated with MLT, at both 40 mg/ 
kg b.w. (subgroup 2A) and 100 mg/kg b.w. (subgroup 2B), 
than in the controls. These differences were more pronoun- 
ced in subgroup 2B, i.e. after higher MLT dose. Furthermore, 
the animals of this subgroup differed significantly from 
the controls in terms of the normalized parameters, namely 
higher nLF and lower nHF. A similar phenomenon was not 
observed in subgroup 2A, i.e. after the smaller MLT dose.
Contrary to the rats treated with MLT, animals treated 
with AMT did not differ significantly from the controls in 
terms of spectral parameters of HRV, with the exception 
of TP and VLF, which achieved significantly higher values 
in rats treated with AMT at 40 mg/kg b.w. The detailed re-
sults of HRV spectral analysis, including statistical conclu-
sions, are presented in Table 3.
 
Discussion
Our most important finding in the analysis of HRV in 
animals with experimental, cyclophosphamide-induced 
hemorrhagic cystitis, treated with either melatonin or ago-
melatine, was to demonstrate that:
1.  Melatonin, administered in rats with cyclophospha-
mide-induced cystitis, modulated ANS activity, causing 
an increase in global autonomic tension. The agent either 
proportionally stimulated both sympathetic and para-
sympathetic part of ANS (at a dose of 40 mg/kg b.w.) or 
preferentially enhanced sympathetic activity (at a dose of 
100 mg/kg b.w.).
2.  Agomelatine, regardless of the applied dose, did not 
exert significant effect on autonomic activity in animals 
with cyclophosphamide-induced cystitis.
3.  Taking into account the fact that AMT, as melatonin 
receptors agonist, did not affect the functional auto-
nomic state, it may be assumed that the modulatory 
effect of MLT on the ANS activity seems to result from 
its non-receptor pharmacodynamic mechanisms (e.g. 
antioxidant activity, regulating the secretion of various 
inflammatory mediators).
Currently, the indirect, non-invasive assessment of the 
autonomic nervous system activity enables the analysis of 
heart rate variability (HRV). The stimulation of sympathet-
ic or parasympathetic ANS branch is reflected by chang-
es in the HRV parameters, both time- and spectral ones. 
According to the commonly accepted interpretative HRV 
guidelines [18, 21, 22, 25], parameters such as SDN-N and 
nLF correlate with sympathetic activity, rMSSD, HF and 
nHF are associated with parasympathetic activity, and the 
power of LF component reflects the activity of both the 
sympathetic and parasympathetic part. Total power (TP) 
of the HRV spectrum is a marker of the global ANS activity.
The interpretation of the part of the HRV spectrum at-
tributing to the range of very low frequency (VLF) is the 
most controversial. The exact mechanisms underlying the 
formation of that spectral component of HRV are still not 
completely understood. The background of VLF includes 
a broad array of various stimuli: thermoregulatory pro-
cesses, the renin-angiotensin-aldosterone system, hae-
modynamics feedback delays, mechanical and central 
neuronal effects of breathing patterns, spinal reflexes or 
vascular autorhythmicity [26]. The VLF power increases 
during sympathetic stimulation (systemic stress, chronic 
heart failure, shock, vasodilatation). On the other hand, 
some evidence suggests that VLF may be of parasympa-
thetic origin. Taylor et al. [27] showed that atropine al-
most completely abolished VLF power and other spectral 
components. Silva Soares et al. [28] also revealed that 
Table 2. Time-domain HRV analysis results (mean ±SD; NS – non-significant). Statistical analysis performed for logarithmic values
Parameter Group 1
Control
Subgroup 2A
MLT 40 mg/kg 
Subgroup 3A
AMT 40 mg/kg 
Statistic p value
1-2A                   1-3A
mean N-N [ms] 160.7 ±9.9 171.2 ±11.3 170.6 ±7.2 0.05 0.02
max N-N [ms] 182.6 ±6.9 188.9 ±3.1 187.1 ±1.2 NS NS
min N-N [ms] 146.2 ±8.3 141.7 ±4.4 147.1 ±9.7 NS NS
average HR [1/min] 375.3 ±23.0 350.7 ±22.8 352.4 ±15.5 0.04 0.01
SD N-N [ms] 6.2 ±2.3 11.2 ±4.5 8.6 ±3.6 0.02 NS
rMSSD [ms] 4.1 ±4.2 9.4 ±8.6 1.4 ±1.8 0.05 0.05
Parameter Group 1
Control
Subgroup 2B
MLT 100 mg/kg 
Subgroup 3B
AMT 100 mg/kg 
Statistic p value
1-2B                 1-3B
mean N-N [ms] 160.7 ±9.9 175.8 ±9.6 167.7 ±5.2 0.01 NS
max N-N [ms] 182.6 ±6.9 188.8 ±5.5 184.9 ±7.0 NS NS
min N-N [ms] 146.2 ±8.3 147.9 ±12.8 149.7 ±11.2 NS NS
average HR [1/min] 375.3 ±23.0 342.2 ±18.9 358.0 ±11.0 0.01 0.03
SD N-N [ms] 6.2 ±2.3 10.1 ±5.2 5.5 ±2.5 0.04 NS
rMSSD [ms] 4.1 ±4.2 10.9 ±8.5 5.2 ±4.3 0.03 NS
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VLF band may be driven by parasympathetic modulation. 
They demonstrated that stimulation with pyridostigmine 
(reversible cholinesterase inhibitor) produced a strong in-
crease in VLF power. Therefore, VLF may also depend on 
the presence of parasympathetic outflow.
Having taken into account the abovementioned inter-
pretative HRV guidelines, the results of our experiment 
support the hypothesis that the administration of mela-
tonin in CP-HC rats produces modulatory effect in relation 
to the ANS activity, the more pronounced the higher MLT 
dose was applied. Administration of MLT (100 mg/kg b.w., 
subgroup 2B) was reflected by evident sympathetic pre-
dominance. This was manifested by an increase in SDN-N 
and nLF and, indirectly, by an increase in VLF and LF (as-
suming sympathetic background of these two parame-
ters).
Contrary to MLT therapy, administration of agomela-
tine did not result in any significant changes in both the 
global autonomic activity and tones of its particular parts. 
As mentioned above, agomelatine is a melatonin receptor 
agonist. Therefore, it may be assumed that modulatory 
properties of MLT did not result from the MT1/2 recep-
tor stimulation, but rather from non-receptor, additional 
pharmacodynamic mechanisms of MLT, related to the an-
tioxidant and inflammation-regulatory properties of this 
agent. The stimulation of the sympathetic part after MLT 
treatment can also result in amelioration of the adrener-
gic-mediated (via β receptors) bladder overactivity (CP-HC 
is associated with some LUTS originating from bladder 
over-contractility).
The abovementioned findings, pointing to a role of MLT 
in the regulation of the autonomic function in CP-HC, are 
also consistent with the results of our previous studies 
which evaluated influence of MLT and AMT on bladder 
motility in an experimental CP-HC model [14]. We revealed 
that MLT (75 or 100 mg/kg b.w.) ameliorated bladder over-
activity observed in the course of experimental CP-HC. On 
the contrary, AMT applied at the same dose, even aggra-
vated dysfunction of bladder contractility, as documented 
on urodynamic recordings. Thus, we showed for the first 
time that the improvement in bladder over-contractility 
after MLT administration may be due to its additional, 
antioxidative and anti-inflammatory properties and is not 
related to MT receptor activation [14].
The beneficial role of MLT, as an antioxidant compound 
used in the CP-HC, was also confirmed by Topal et al. [29]. 
They showed that melatonin exerted significant protective 
effect against CP-induced cystitis by diminishing bladder 
oxidative stress and blocking inducible nitric oxide syn-
thase and peroxynitrite production. They also postulated 
that oxidants may play a major role in the pathogenesis 
of CP-HC, and thus MLT seems to be one of the new, most 
promising candidates to ameliorate bladder damage in-
duced by CP. The findings of Topal et al. were confirmed by 
Sadir et al. [30] who also demonstrated that α-tocopherol 
and melatonin show meaningful protective effect against 
bladder damage in CP-HC rats. More detailed study aimed 
to assess MLT influence on bladder inflammatory process 
in CP-HC model was performed by Zhang et al. [31]. They 
analysed the expressions of heme oxygenase-1 (HO-1), in-
ducible nitric oxide synthase (iNOS) and substance P (SP), 
and demonstrated that melatonin significantly attenuated 
bladder symptoms and histological damage in CP-HC rats 
by diminishing bladder oxidative stress, blocking iNOS, 
up-regulating HO-1, and down-regulating the expression 
of SP. On a margin, the beneficial effect of MLT on bladder 
injury was also revealed in other than CP-induced models. 
Cetinel et al. [32] investigated the effects of melatonin on 
protamine sulphate-induced bladder injury and demon-
strated that bladder malondialdehyde level was decreased 
in MLT-treated rats. 
To summarize, there are some reports indicating that 
antioxidative and anti-inflammatory features of MLT may 
result in attenuation of a CP-induced bladder injury. Our 
study confirmed once again the non-receptor nature of the 
potential, uroprotective effects exerted by MLT in CP-HC, 
Table 3. Spectral-domain HRV analysis results (mean ±SD; NS – non-significant). Statistical analysis performed for logarithmic values
Parameter Group 1
Control
Subgroup 2A
MLT 40 mg/kg 
Subgroup 3A
AMT 40 mg/kg 
Statistic p value
1-2A                   1-3A
TP [ms2] 11.1 ±14.1 49.5 ±53.5 19.6 ±6.9 0.05 0.01
VLF [ms2] 7.4 ±8.7 39.1 ±45.2 17.2 ±6.9 0.05 0.01
LF [ms2] 1.4 ±2.1 5.5 ±5.8 1.2 ±1.1 0.05 NS
HF [ms2] 2.4 ±3.5 4.9 ±4.1 1.3 ±1.2 0.04 NS
nLF [n.u.] 40.0 ±20.6 40.9 ±18.9 37.7 ±26.0 NS NS
nHF [n.u.] 60.0 ±20.5 59.1 ±18.9 62.3 ±26.0 NS NS
Parameter Group 1
Control
Subgroup 2B
MLT 100 mg/kg 
Subgroup 3B
AMT 100 mg/kg 
Statistic p value
1-2B                    1-3B
TP [ms2] 11.1 ±14.1 58.6 ±47.1 17.8 ±20.3 0.01 NS
VLF [ms2] 7.4 ±8.7 47.3 ±38.2 11.0 ±15.3 0.01 NS
LF [ms2] 1.4 ±2.1 6.2 ±5.4 1.8 ±2.7 0.02 NS
HF [ms2] 2.4 ±3.5 5.1 ±4.3 4.9 ±8.0 0.03 NS
nLF [n.u.] 40.0 ±20.6 55.9 ±5.9 32.2 ±20.4 0.04 NS
nHF [n.u.] 60.0 ±20.5 44.1 ±5.9 67.8 ±20.4 0.03 NS
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and showed that the beneficial effects of this compound 
may be partially caused by the reorganization of the ANS 
status with the sympathovagal balance shifted towards 
sympathetic overdrive. The increased sympathetic func-
tion and global autonomic tension, observed in exper-
imental CP-HC after a large MLT dose, improve bladder 
compliance and can contribute to alleviating of some LUTS 
resulting from bladder overactivity. Our findings, as well 
as the results of the abovementioned previous studies, 
justify further research on the beneficial role of MLT in the 
CP-HC. The future studies may lead to official approval of 
MLT as yet another new uroprotector reducing the toxicity 
of cyclophosphamide.
The authors declare no conflict of interest.
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